2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
February 2024 in “BMJ Open” The study concluded that different treatments reduced post-COVID symptoms over time and that factors like age, severity, and comorbidities affect symptom risk.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
84 citations
,
March 2010 in “Infectious Disease Clinics of North America” The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
52 citations
,
September 2021 in “Kidney International” COVID-19 vaccination may trigger lupus in some people.